Samantha Tam1, Mona Gajera2, Xiaoning Luo2, Bonnie S Glisson3, Renata Ferrarotto3, Faye M Johnson3,4, Frank E Mott3, Maura L Gillison3,4, Charles Lu3, Xiuning Le3, George R Blumenschein3, Michael K Wong5, David I Rosenthal6, Priyadharsini Nagarajan7, Adel K El-Naggar7, Michael R Midgen8, Randal S Weber2, Jeffrey N Myers2,4, Neil D Gross2. 1. Department of Otolaryngology - Head and Neck Surgery, Henry Ford Health System and Henry Ford Cancer Institute, Detroit, Michigan, USA. 2. Division of Surgery, Department of Head and Neck Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. 3. Division of Cancer Medicine, Department of Thoracic Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. 4. The University of Texas Graduate School of Biomedical Sciences, Houston, Texas, USA. 5. Division of Cancer Medicine, Department of Melanoma Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. 6. Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. 7. Division of Pathology/Lab Medicine, Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. 8. Division of Internal Medicine, Department of Dermatology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.
Abstract
BACKGROUND: The outcomes of patients treated with cytotoxic or targeted systemic therapy is not well defined for cutaneous squamous cell carcinoma of the head and neck (cSCCHN). METHODS: Patients with cSCCHN treated with cytotoxic or targeted systemic therapy were included. Patients were divided into two groups based on the presence of distant metastasis (M1 vs. M0) at presentation. A proportional hazards model was used to assess for independent predictors of overall survival. RESULTS: Of 129 patients with cSCCHN, 20 (16%) were M1 and 109 (84%) were M0. Independent predictors of improved survival were M0 status, treatment of locally advanced disease with radiotherapy, and lower Eastern Cooperative Oncology Group (ECOG) score. CONCLUSIONS: Survival was worse in M1 patients treated with cytotoxic or targeted systemic therapy and poor baseline performance status but improved in those receiving radiotherapy. These data can serve as historical controls for future systemic therapy trials, including immunotherapy.
BACKGROUND: The outcomes of patients treated with cytotoxic or targeted systemic therapy is not well defined for cutaneous squamous cell carcinoma of the head and neck (cSCCHN). METHODS:Patients with cSCCHN treated with cytotoxic or targeted systemic therapy were included. Patients were divided into two groups based on the presence of distant metastasis (M1 vs. M0) at presentation. A proportional hazards model was used to assess for independent predictors of overall survival. RESULTS: Of 129 patients with cSCCHN, 20 (16%) were M1 and 109 (84%) were M0. Independent predictors of improved survival were M0 status, treatment of locally advanced disease with radiotherapy, and lower Eastern Cooperative Oncology Group (ECOG) score. CONCLUSIONS: Survival was worse in M1 patients treated with cytotoxic or targeted systemic therapy and poor baseline performance status but improved in those receiving radiotherapy. These data can serve as historical controls for future systemic therapy trials, including immunotherapy.